Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederendpts.com
ENDPOINTS NEWS
Get the latest updates from ENDPOINTS NEWS directly as they happen.
Follow now 178 followers
Latest posts
Last updated 8 minutes ago
Entrada stock falls on Duchenne data; Wegovy expands access
9 minutes ago
Plus, news about BioCryst, GSK and Roche 🙃 Entrada’s Duchenne drug disappoints:...
Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany
about 1 hour ago
Plus, news about FDA's one-day inspections and BioMADE 🇵🇷 Amgen pours another...
Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
about 2 hours ago
There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics...
Pennsylvania sues AI chatbot company for posing as a licensed doctor
about 3 hours ago
The state of Pennsylvania has sued Character.AI, a startup that lets users...
Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma
about 5 hours ago
Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its...
Amgen, AbbVie say IRA negotiations impacted Q1 sales
about 20 hours ago
At least two drugmakers say they’re feeling the impact of the Inflation...
Lilly plans new $4.5B manufacturing investment in Indiana
about 21 hours ago
Eli Lilly is committing to its roots, allocating $4.5 billion for new...
BeOne culls five cancer programs and an autoimmune Phase 2
about 21 hours ago
BeOne Medicines has greatly expanded its pipeline over the years, bringing 18...
Lonza looks to ride ADC wave with upcoming factory, workforce expansion
about 21 hours ago
BASEL, Switzerland — Lonza said it wants to own the commercial market...
Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts
about 24 hours ago
🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came...
Former Orbital scientists launch new mRNA therapy startup
about 24 hours ago
Two scientists think they've solved a technical problem that has kept the...
Avalo scores Phase 2 success in comeback bid, raises $375M
1 day ago
Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech...